BPC-157 (Oral) vs KPV
A side-by-side research comparison of BPC-157 (Oral) and KPV across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | KPV |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Lysine-Proline-Valine Tripeptide |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation. |
| Molecular weight | 1419.53 Da | 342.43 Da |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~2-3 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | ~60-70% oral; higher subcutaneous |
| Typical dose | 500 mcg - 1 mg | 200-500 mcg per dose |
| Frequency | 1-2x daily | 1-2x daily |
| Route | Oral capsule (arginate salt) | Oral, topical, or subcutaneous |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
KPV reported benefits
- Potent anti-inflammatory
- Gut inflammation reduction
- Skin condition improvement
- Immune modulation
Related comparisons
Research and educational reference only. Not medical advice.